trial

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

NCTId NCT01515423
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 1,429 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2015-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
1,429 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-05
Primary completion
2015-02
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
PP3M 175 mg eq.PP3M 263 mg eq.PP3M 350 mg eq.PP3M 525 mg eq.PP1M 50 mg eq.PP1M 75 mg eq.PP1M 100 mg eq.PP1M 150 mg eq.

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Linked catalysts

1
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatme — primary completion2015-02

Facts & assertions

4 sourced
Enrollment
1,429
Phase
PHASE3
Primary Completion Date
2015-02
Status
COMPLETED
relationships
The graph out of here
drug
PP3M 175 mg eq.
drug
PP3M 263 mg eq.
drug
PP3M 350 mg eq.
drug
PP3M 525 mg eq.
drug
PP1M 50 mg eq.
drug
PP1M 75 mg eq.
drug
PP1M 100 mg eq.
drug
PP1M 150 mg eq.
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication